一切旧貌换新颜：HER2阳性乳腺癌中的细胞衰老 - Suppr | 超能文献

Everything old is neu again: cellular senescence in HER2-positive breast cancer.

作者信息

Sledge George W, Pegram Mark D

机构信息

Stanford Cancer Institute, Stanford University, Stanford, CA (GWS, MDP).

出版信息

J Natl Cancer Inst. 2015 May 13;107(5). doi: 10.1093/jnci/djv091. Print 2015 May.

DOI:10.1093/jnci/djv091

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Everything old is neu again: cellular senescence in HER2-positive breast cancer.一切旧貌换新颜：HER2阳性乳腺癌中的细胞衰老

J Natl Cancer Inst. 2015 May 13;107(5). doi: 10.1093/jnci/djv091. Print 2015 May.

2

HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.人表皮生长因子受体2阳性乳腺癌、内在亚型与个体化治疗

J Natl Cancer Inst. 2014 Aug 19;106(8). doi: 10.1093/jnci/dju212. Print 2014 Aug.

3

Ribociclib in HR-positive, HER2-negative breast cancer.瑞博西尼用于激素受体阳性、人表皮生长因子受体2阴性乳腺癌

Lancet Oncol. 2016 Nov;17(11):e482. doi: 10.1016/S1470-2045(16)30502-2. Epub 2016 Oct 13.

4

Choline as a biomarker for cell proliferation: do the results from proton MR spectroscopy show difference between HER2/neu positive and negative breast cancers?胆碱作为细胞增殖的生物标志物：质子磁共振波谱分析结果显示HER2/neu阳性和阴性乳腺癌之间存在差异吗？

Int J Cancer. 2008 Sep 1;123(5):1219-21. doi: 10.1002/ijc.23552.

5

[HER2-positive breast cancer: standard and double targeted therapy].[人表皮生长因子受体2阳性乳腺癌：标准治疗与双重靶向治疗]

Vopr Onkol. 2013;59(3):341-6.

6

Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.趋化因子受体CXCR4在乳腺癌中的表达作为骨髓中孤立肿瘤细胞的潜在预测标志物。

Clin Exp Metastasis. 2005;22(1):39-46. doi: 10.1007/s10585-005-3222-y.

7

Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.曲妥珠单抗与化疗联合使用可能对患有小的、无淋巴结转移的、人表皮生长因子受体2阳性乳腺癌的女性有效。

J Clin Oncol. 2015 Jan 1;33(1):124-5. doi: 10.1200/JCO.2014.58.2965. Epub 2014 Nov 17.

8

Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?新辅助化疗前后的乳腺癌生物标志物：重复检测是否会影响治疗管理？

Hum Pathol. 2017 Apr;62:215-221. doi: 10.1016/j.humpath.2016.12.019. Epub 2016 Dec 30.

9

Does HER-2 status predict only a decreased response to hormone therapy in advanced breast cancer, or does it also predict the extent of metastatic disease?HER-2状态仅仅预示晚期乳腺癌患者对激素治疗的反应降低，还是也能预示转移疾病的程度？

J Clin Oncol. 2002 Dec 1;20(23):4605; author reply 4606. doi: 10.1200/JCO.2002.99.191.

10

How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.我们应该降到多低？探索人表皮生长因子受体2阳性小乳腺癌管理中的平衡

J Clin Oncol. 2014 Jul 10;32(20):2122-4. doi: 10.1200/JCO.2014.55.7249. Epub 2014 Jun 2.

引用本文的文献

1

Loss of BRG1 induces CRC cell senescence by regulating p53/p21 pathway.BRG1的缺失通过调节p53/p21通路诱导结直肠癌细胞衰老。

Cell Death Dis. 2017 Feb 9;8(2):e2607. doi: 10.1038/cddis.2017.1.

2

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.使用乳腺癌患者来源的异种移植模型进行抗白细胞介素-6治疗。

Oncotarget. 2016 Oct 18;7(42):67956-67965. doi: 10.18632/oncotarget.11815.